Table I.
Clinical and pathological features of the patient cohort.
| Patient | Sex | Age (years) | Location of the primary MM | Breslow | BRAF status | Metastasis sites | TNM stage before anti PD-1 therapy | Line of therapy | Start of anti PD-1 therapy | Last follow-up | Status | Type of response | OS (days) | PFS (days) | MMR status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 82 | Back | 2 | V600E | Skin, lungs, perirenal | 4b | I | 19/05/16 | 11/07/17 | Alive | CR | 572 | 418 | MMR stable |
| 2 | M | 84 | Head and neck | 11 | WT | Skin, lymph node | 3c | II | 14/04/16 | 16/08/16 | Dead | PD | 154 | 124 | MMR stable |
| 3 | M | 83 | Upper limbs | 4 | WT | Lungs, lymph node | 4b | I | 12/07/16 | 26/11/16 | Dead | PD | 213 | 81 | MMR stable |
| 4 | M | 73 | Back | 2 | WT | Lung, bone, spleen, liver, lymph node | 4c | I | 07/07/16 | 27/06/17 | Alive | PR | 406 | 355 | MMR stable |
| 5 | M | 83 | Lower limbs | 3 | WT | Lymph node, muscle, retroperitoneal | 4a | I | 21/08/16 | 11/07/17 | Alive | CR | 335 | 324 | MMR stable |
| 6 | M | 55 | Back | 15 | V600E | Lymph node, skin | 4a | II | 13/05/16 | 19/11/16 | Dead | PD | 1,040 | 125 | MMR stable |
| 7 | F | 76 | Lower limbs | 7 | WT | Skin | 4a | II | 15/03/16 | 11/07/17 | Alive | PD | 719 | 457 | MMR stable |
| 8 | M | 57 | Back | 4 | V600K | Lymph node, lungs, skin, liver, spleen, brain | 4c | II | 15/05/16 | 03/09/16 | Dead | PD | 201 | 93 | MMR stable |
| 9 | M | 86 | Acral | 2 | WT | Lungs, pancreatic, pararenal | 4d | II | 28/01/16 | 12/10/16 | Dead | PD | 368 | 196 | MMR stable |
| 10 | M | 77 | Back | 3 | WT | Lungs, lymph node, bowel, muscle | 4b | III | 15/09/14 | 19/09/16 | Dead | PD | 1,496 | 517 | MMR stable |
| 11 | F | 48 | Acral | 1,4 | WT | Kidney, lymph node, lungs, bone, brain, bowel | 4d | V | 21/11/14 | 04/07/17 | Alive | CR | 2,546 | 956 | Loss of MSH6 expression |
| 12 | M | 57 | Chest | 13 | V600E | Skin, liver, spleen, lungs, bone | 4c | II | 11/10/16 | 11/07/17 | Alive | PD | 94 | 84 | MMR stable |
| 13 | M | 47 | Chest | 3 | V600E | Lungs | 4b | I | 23/08/16 | 11/07/17 | Alive | PR | 361 | 322 | MMR stable |
| 14 | M | 88 | Head and neck | 11 | WT | Lungs, brain | 4d | III | 18/06/15 | 01/07/17 | Dead | PR | 1,088 | 684 | MMR stable |
M, male; F, female; WT, wild-type; V600E, substitution of valine to glutamic acid at codon 600; c.1799 T>A; V600K, substitution of valine to lysine at codon 600; c.1798_1799 GT>AA; CR, complete response; PD, anti PD-1; MM, malignant melanoma; OS, overall survival; PFS, progression-free survival; PR, partial response, Breslow, Breslow levels; MMR, mismatch repair status.